单剂量地塞米松对唑来膦酸后急性期反应的影响:一项随机对照试验
这项双盲随机对照试验纳入40例首次接受唑来膦酸5 mg静脉治疗的成人,比较口服地塞米松4 mg(n=20)与安慰剂(n=20)对急性期反应的影响。结果显示,地塞米松组与安慰剂组在体温变化、症状评分及解救药物使用上均无显著差异。单剂量地塞米松4 mg不影响唑来膦酸首次暴露后急性期反应的发生率或严重程度。
要点
- 地塞米松组与安慰剂组体温变化无显著差异(p=0.95)。
- 地塞米松组55%与安慰剂组50%出现体温升高≥1°C(p=0.99)。
- 地塞米松组65%与安慰剂组60%需解救药物(p=0.99)。
核心结论
- 单剂量地塞米松4 mg不影响首次暴露于唑来膦酸后急性期反应的发生率或严重程度。
研究设计与样本
- 双盲、随机、对照试验评估40例首次接受唑来膦酸5 mg静脉治疗的成人。
- 参与者在地塞米松4 mg口服(n=20)或安慰剂(n=20)组于唑来膦酸输注时给药。
- 主要结局为基线与输注后3天内体温变化的组间差异。
主要发现
- 地塞米松组与安慰剂组在唑来膦酸后3天内体温变化无显著差异(p=0.95),症状评分无显著差异(p=0.42)。
- 地塞米松组11例(55%)与安慰剂组10例(50%)出现体温升高≥1°C(p=0.99)。
- 地塞米松组7例(35%)与安慰剂组9例(45%)出现症状评分增加≥3分(p=0.75)。
- 地塞米松组13例(65%)与安慰剂组12例(60%)需要解救药物(p=0.99)。
- 地塞米松耐受良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Zoledronic acid provokes an inflammatory reaction, or acute phase response, in some individuals. We examined whether treatment with dexamethasone could prevent this response. A single dose of dexamethasone 4 mg, given at the time of zoledronic acid infusion, did not influence the incidence or severity of the acute phase response. INTRODUCTION: The potent bisphosphonate zoledronic acid (ZOL) is used to treat osteoporosis, Paget's disease, and hypercalcemia of malignancy. This medication can provoke an inflammatory reaction, known as the acute phase response (APR). We examined whether glucocorticoid treatment at the time of first exposure to ZOL prevents the development of APR. METHODS: This double-blind, randomized, controlled trial assessed 40 adults receiving ZOL 5 mg intravenously for the first time. Participants received oral dexamethasone 4 mg (n = 20) or placebo (n = 20) at the time of ZOL infusion. Oral temperature was measured at baseline and three times a day for 3 days following infusion. Symptoms of APR were assessed via questionnaire at baseline then daily for 3 days and again at day 15 post-infusion. Use of rescue medications (paracetamol or ibuprofen) in the 3 days following infusion was evaluated. Primary outcome was between-group difference in temperature change from baseline. RESULTS: There was no significant difference in temperature change (p = 0.95) or symptom score (p = 0.42) in the 3 days following ZOL between dexamethasone and placebo recipients. Eleven (55%) in the dexamethasone group and 10 (50%) placebo recipients experienced a temperature increase of ≥1 °C (p = 0.99). Seven (35%) in the dexamethasone group and 9 (45%) in the placebo group experienced an increase in symptom score of ≥3 points (p = 0.75). Thirteen (65%) dexamethasone recipients and 12 (60%) in the placebo group required rescue medications (p = 0.99). Dexamethasone was well-tolerated. CONCLUSIONS: A single dose of dexamethasone 4 mg does not influence the incidence or severity of APR following first exposure to ZOL. TRIAL REGISTRATION: ACTRN12615000794505.
引用
- Billington EO, Horne A, Gamble GD, et al. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporos Int. 2017. PMID: 28233020. doi:10.1007/s00198-017-3960-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。